puc-header

Timing the Initiation of Multiple Myeloma

122 Pages Posted: 25 Jun 2019 Publication Status: Review Complete

See all articles by Even H. Rustad

Even H. Rustad

Memorial Sloan Kettering Cancer Center - Myeloma Service

Venkata Yellapantula

Memorial Sloan Kettering Cancer Center - Myeloma Service

Niccolo Bolli

University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department

Daniel Leongamornlert

Wellcome Sanger Institute

Ferran Nadeu

University of Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

Nicos Angelopoulos

University of Essex

Kevin J. Dawson

Wellcome Sanger Institute

Thomas J. Mitchell

Wellcome Sanger Institute

Rob Osborne

Wellcome Sanger Institute

Bachisio Ziccheddu

University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department

Cristiana Cariniti

Fondazione IRCCS Istituto Nazionale dei Tumori

Vittorio Montefusco

Fondazione IRCCS Istituto Nazionale dei Tumori - Division of Hematology and Bone Marrow Transplantation

Paolo Corradini

University of Milan

Kenneth C. Anderson

Harvard University - Dana-Farber Cancer Institute

Philippe Moreau

University of Nantes

Elli Papaemmanuil

Memorial Sloan Kettering Cancer Center - Myeloma Service

Ludmil Alexandrov

University of California, San Diego (UCSD) - Moores Cancer Center

Xose S. Puente

University of Barcelona

Elias Campo

Patologia Molecular de Neoplàsies Limfoides, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

Reiner Siebert

Ulm University

Herve Avet-Loiseau

IUC-Oncopole

Ola Landgren

Memorial Sloan Kettering Cancer Center - Myeloma Service

Nikhil Munshi

Harvard University - Dana-Farber Cancer Institute

Peter J. Campbell

Wellcome Genome Campus - Cancer Genome Project; Wellcome Trust Sanger Institute

Francesco Maura

Memorial Sloan Kettering Cancer Center - Myeloma Service

More...

Abstract

The evolution and progression of multiple myeloma (MM) and its precursors over time is poorly understood. Here, we investigated the landscape and timing of mutational processes shaping MM evolution in a large cohort of 89 whole genomes and 973 exomes. Eight processes were identified, including a new mutational signature associated with exposure to alkylating agents. Reconstructing the chronological activity of each mutational signature, we estimated that initial transformation of a germinal center B-cell usually occurred during the first 2-3 decades of life. From there the transformed cells followed one of four main trajectories to MM, each reflecting a distinct order of mutational processes driving tumor evolution. Our findings provide a framework to study the etiology of MM and explore strategies for prevention and early detection.

Keywords: Multiple Myeloma, Mutational Signatures, Molecular Time, Cancer Initiation, Germinal Center

Suggested Citation

Rustad, Even H. and Yellapantula, Venkata and Bolli, Niccolo and Leongamornlert, Daniel and Nadeu, Ferran and Angelopoulos, Nicos and Dawson, Kevin J. and Mitchell, Thomas J. and Osborne, Rob and Ziccheddu, Bachisio and Cariniti, Cristiana and Montefusco, Vittorio and Corradini, Paolo and Anderson, Kenneth C. and Moreau, Philippe and Papaemmanuil, Elli and Alexandrov, Ludmil and Puente, Xose S. and Campo, Elias and Siebert, Reiner and Avet-Loiseau, Herve and Landgren, Ola and Munshi, Nikhil and Campbell, Peter J. and Maura, Francesco, Timing the Initiation of Multiple Myeloma (June 25, 2019). Available at SSRN: https://ssrn.com/abstract=3409453 or http://dx.doi.org/10.2139/ssrn.3409453
This version of the paper has not been formally peer reviewed.

Even H. Rustad

Memorial Sloan Kettering Cancer Center - Myeloma Service

United States

Venkata Yellapantula

Memorial Sloan Kettering Cancer Center - Myeloma Service

United States

Niccolo Bolli

University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department

Italy

Daniel Leongamornlert

Wellcome Sanger Institute

Hinxton, Saffron Walden
Cambridge, England CB10 1SA
United Kingdom

Ferran Nadeu

University of Barcelona - Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

Barcelona
Spain

Nicos Angelopoulos

University of Essex

Wivenhoe Park
Colchester, CO4 3SQ
United Kingdom

Kevin J. Dawson

Wellcome Sanger Institute

Hinxton, Saffron Walden
Cambridge, England CB10 1SA
United Kingdom

Thomas J. Mitchell

Wellcome Sanger Institute

Hinxton, Saffron Walden
Cambridge, England CB10 1SA
United Kingdom

Rob Osborne

Wellcome Sanger Institute

Hinxton, Saffron Walden
Cambridge, England CB10 1SA
United Kingdom

Bachisio Ziccheddu

University of Milan, Faculty of Medicine, Oncology and Hemato-Oncology Department

Italy

Cristiana Cariniti

Fondazione IRCCS Istituto Nazionale dei Tumori

Via Giacomo Venezian, 1
Milano MI, 20133
Italy

Vittorio Montefusco

Fondazione IRCCS Istituto Nazionale dei Tumori - Division of Hematology and Bone Marrow Transplantation ( email )

via Venezian 1
Milan, 20133
Italy

Paolo Corradini

University of Milan

Via Festa del Perdono, 7
Milan, 20122
Italy

Kenneth C. Anderson

Harvard University - Dana-Farber Cancer Institute

450 Brookline Avenue
Boston, MA 02215
United States

Philippe Moreau

University of Nantes

1, quai de Tourville BP
Nantes Cedex 1
Nantes, 44313
France

Elli Papaemmanuil

Memorial Sloan Kettering Cancer Center - Myeloma Service

United States

Ludmil Alexandrov

University of California, San Diego (UCSD) - Moores Cancer Center

1503, 3855 Health Sciences Dr.
La Jolla, CA 92093
United States

Xose S. Puente

University of Barcelona

Gran Via de les Corts Catalanes, 585
Barcelona, 08007
Spain

Elias Campo

Patologia Molecular de Neoplàsies Limfoides, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)

Spain

Reiner Siebert

Ulm University

Albert-Einstein-Alee 11
Ulm, D-89081
Germany

Herve Avet-Loiseau

IUC-Oncopole

France

Ola Landgren

Memorial Sloan Kettering Cancer Center - Myeloma Service

United States

Nikhil Munshi

Harvard University - Dana-Farber Cancer Institute

450 Brookline Avenue
Boston, MA 02215
United States

Peter J. Campbell

Wellcome Genome Campus - Cancer Genome Project

Hinxton, Saffron Walden
Cambridge, England CB10 1SA
United Kingdom

Wellcome Trust Sanger Institute

Hinxton, Saffron Walden
Cambridge, England CB10 1SA
United Kingdom

Francesco Maura (Contact Author)

Memorial Sloan Kettering Cancer Center - Myeloma Service ( email )

United States

Click here to go to Cell.com

Paper statistics

Downloads
84
Abstract Views
1,772
PlumX Metrics